- Policy
- Pfizer, challenges Velcade’s generic market
- by Lee, Tak-Sun Jan 22, 2020 10:47pm
- Pfizer will show anticancer generics (Pfizer Bortezomib, generic for Velcade) used in multiple myeloma. It is expected to compete with the original drug by Janssen and six domestic generics. The MFDS approved the Pfizer Bortezomib 3.5 mg of Pfizer Korea on the 21st. It is the same ingredient of Janssen Korea’s Velcade (Bortezomib). The
- Company
- Eliquis flying out to space and saving an astronaut?
- by Eo, Yun-Ho Jan 22, 2020 10:47pm
- Apparently, anticoagulant Eliquis (Apixaban) has been delivered to outer space. This was the first outer space deep vein thrombosis (DVT) treatment and prescription in the history. The details were revealed when an article titled ‘Venous Thrombosis during Spaceflight’ was published in New England Journal of Medicine (NEJM).
- Company
- BMS-Celgene to maintain independent offices this year
- by Eo, Yun-Ho Jan 22, 2020 06:29am
- Bristol-Myers Squibb (BMS) and Celgene have agreed to maintain the independent administrative system until the end of the year. According to pharmaceutical industry sources, BMS Korea Pharmaceutical and Celgene Korea have recently convened a town hall meeting to discuss the post-merge operational plan for the Korean offshoots, and have d
- Company
- Despite No Japan movement, Japanese companies performed well
- by An, Kyung-Jin Jan 22, 2020 06:28am
- In the prescription drug market, there was no aftermath of a Japanese boycott. Since July, when the Japanese government began to regulate exports, outpatient prescriptions by Japanese pharmaceutical companies have increased. The high severity of disease and the proportion of original drugs have unaffected by the boycott. According to UB
- Company
- Anti-obesity drug market stirred by lorcaserin safety issue
- by Jung, Hye-Jin Jan 22, 2020 06:27am
- Anti-obesity drug companies are on high alert as a safety issue has surfaced regarding lorcaserin, an active ingredient used for in anti-obesity medication.. Lorcaserin competitors are also getting busy anticipating doctors and pharmacists to avoid Ildong Pharmaceutical’s Belviq (locarserin), which was considered a safe anti-obesity drug
- Policy
- The leukemia drug 'Venclexta', formulary approved
- by Lee, Hye-Kyung Jan 22, 2020 06:27am
- Venclexta (Venetoclax), a drug used to treat chronic lymphocytic leukemia (CLL) that by Abbvie Korea, got formulary approval. The HIRA announced in December last year that Venclexta 10 mg, 50 mg and 100 mg were adequate for their benefits. Abbvie received Venclexta’s permission from the Ministry of Food and Drug Safety on May 29, and
- Policy
- Naglazyme RSA ends, 20.6% price cut from March
- by Kim, Jung-Ju Jan 22, 2020 06:27am
- Insurance prices have fallen by more than 20% since March, when Naglazyme (Galsulfaze) by Samoh Pharmaceutical has concluded a risk-sharing contract (RSA) agreement. According to pharmaceutical companies' strategies, such as price competition, there are a total of eight products that will be lowered on their own benefits next month. Accord
- InterView
- “Changing the public’s view on psoriasis patients”
- by An, Kyung-Jin Jan 22, 2020 06:27am
- “Too many people had no or wrong idea about psoriasis. We opened the crowd funding to raise awareness of psoriasis and to improve the public’s perception on the disease.” A university student-centered crowd funding union, ‘Wishtree’ opened a new funding project this month. The project aims to help patients with psoriasis. Althou
- Company
- AstraZeneca retries expanding Tagrisso's reimbursement
- by Eo, Yun-Ho Jan 21, 2020 06:25am
- Target therapy Tagrisso is trying to resume the reimbursement review procedure for its indication as a first-line lung cancer treatment. According to pharmaceutical industry source, AstraZeneca Korea has submitted a reimbursement expansion application at the end of last year for the first-line indication of its epidermal growth factor re
- Policy
- Nabota, Phase III clinical trial will be conducted
- by Lee, Tak-Sun Jan 21, 2020 06:25am
- Daewoong's botulinum toxin preparation 'Nabota' is speeding up the indication of treatment as well as improving the wrinkles of the glans. Nabota, which has four indications, is in the final phase of clinical trials to prove the effectiveness of improving the square jaw. The Ministry of Food and Drug Safety approved the Phase III clinic
